ELICIO THERAPEUTICS INC (ELTX)

Elicio Therapeutics Announces Pricing of $11.5 Million Underwritten Public Offering

Elicio Therapeutics Announces Pricing of $11.5 Million Underwritten Public Offering

BOSTON, June 28, 2024 (GLOBE NEWSWIRE) -- Elicio Therapeutics, Inc. (Nasdaq: ELTX, “Elicio Therapeutics” or “Elicio”), a clinical-stage biotechnology...

Why Is Elicio Therapeutics (ELTX) Stock Down 36% Today?

Elicio Therapeutics stock is down on Friday after the company announced a proposed public offering for shares of ELTX this morning.

Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Friday

Pre-market stock movers are a hot topic on Friday and we're breaking down all of the latest news sending shares higher and lower!

Elicio Therapeutics Announces Proposed Public Offering

BOSTON, June 27, 2024 (GLOBE NEWSWIRE) -- Elicio Therapeutics, Inc. (Nasdaq: ELTX, “Elicio Therapeutics” or “Elicio”), a clinical-stage biotechnology...

Elicio Therapeutics Announces Proposed Public Offering

Elicio Therapeutics Announces Preliminary Disease-Free Survival analysis from the Ongoing AMPLIFY-7P Phase 1a Study of ELI-002 7P

ELI-002 7P administered as a monotherapy at the Phase 2 dose shows preliminary encouraging Disease-Free Survival data in pancreatic ductal adenocarcinoma

Elicio Therapeutics Announces Preliminary Disease-Free Survival analysis from the Ongoing AMPLIFY-7P Phase 1a Study of ELI-002 7P

ELI-002 7P administered as a monotherapy at the Phase 2 dose shows preliminary encouraging Disease-Free Survival data in pancreatic ductal adenocarcinoma...

Elicio Therapeutics Reports Inducement Grants

BOSTON, June 18, 2024 (GLOBE NEWSWIRE) -- Elicio Therapeutics, Inc. (Nasdaq: ELTX, “Elicio Therapeutics” or “Elicio”), a clinical-stage biotechnology...

Elicio Therapeutics Announces Preliminary Data from the Ongoing AMPLIFY-7P Phase 1a Study of ELI-002 7P in Patients with mKRAS-driven Solid Tumors at the 2024 ASCO Annual Meeting

ELI-002 7P administered as a monotherapy was well tolerated and able to generate a ~100x mKRAS-specific expanded T cell response relative to baseline...

ELTX Stock Earnings: Elicio Therapeutics Beats EPS for Q1 2024

InvestorPlace - Stock Market News, Stock Advice & Trading Tips Elicio Therapeutics (NASDAQ:ELTX) just reported results for the first quarter o...

ELTX Stock Earnings: Elicio Therapeutics Beats EPS for Q1 2024

ELTX stock results show that Elicio Therapeutics beat analyst estimates for earnings per share the first quarter of 2024.

Elicio Therapeutics Reports First Quarter 2024 Financial Results and Provides Corporate Updates

ELI-002 2P Phase 1 preliminary data published in Nature Medicine ELI-002 2P Phase 1 data characterizing the CD4 and CD8 profile of the KRAS immune response...

Elicio Therapeutics to Present New Preliminary Data from the Ongoing AMPLIFY-7P Phase 1/2 Study of ELI-002 7P in Patients with mKRAS-driven Solid Tumors at the 2024 ASCO Annual Meeting

BOSTON, April 25, 2024 (GLOBE NEWSWIRE) -- Elicio Therapeutics, Inc. (Nasdaq: ELTX, “Elicio Therapeutics” or “Elicio”), a clinical-stage biotechnology...

Elicio Therapeutics to Present Updated Clinical T Cell and Antigen Spreading Response Data from the Ongoing AMPLIFY-201 Phase 1 Study of ELI-002 and Preclinical Data on ELI-007 and ELI-008 at the AACR Annual Meeting

68% of patients treated with ELI-002 developed cytotoxic mKRAS-specific CD4+ T cells84% of patients treated with ELI-002 developed cytotoxic mKRAS-specific...

ELTX Stock Earnings: Elicio Therapeutics Misses EPS for Q4 2023

ELTX stock results show that Elicio Therapeutics missed analyst estimates for earnings per share the fourth quarter of 2023.

ELTX Stock Earnings: Elicio Therapeutics Misses EPS for Q4 2023

InvestorPlace - Stock Market News, Stock Advice & Trading Tips Elicio Therapeutics (NASDAQ:ELTX) just reported results for the fourth quarter ...

Elicio Therapeutics Reports 2023 Financial Results and Provides Corporate Updates

ELI-002 2P clinical immunogenicity data were accepted for a poster presentation at the AACR Annual Meeting 2024ELI-007 and ELI-008 preclinical data were...

Elicio Therapeutics Announces $6.0 Million Private Placement Financing

BOSTON, March 18, 2024 (GLOBE NEWSWIRE) -- Elicio Therapeutics, Inc. (Nasdaq: ELTX, “Elicio Therapeutics” or “Elicio”), a clinical-stage biotechnology...

Elicio Therapeutics Announces Upcoming Presentations at the American Association for Cancer Research (AACR) Annual Meeting

BOSTON, March 06, 2024 (GLOBE NEWSWIRE) -- Elicio Therapeutics, Inc. (Nasdaq: ELTX, “Elicio Therapeutics” or “Elicio”), a clinical-stage biotechnology...

Elicio Therapeutics to Present at the Oppenheimer 34th Annual Healthcare Life Sciences Conference

Elicio Therapeutics to Present at the Oppenheimer 34th Annual Healthcare Life Sciences Conference

BOSTON, Feb. 05, 2024 (GLOBE NEWSWIRE) -- Elicio Therapeutics, Inc. (Nasdaq: ELTX, “Elicio Therapeutics” or “Elicio”), a clinical-stage biotechnology...

Elicio Therapeutics Announces Publication of Preclinical Data Demonstrating TCR-T Cell Therapy in Combination with Lymph Node-Targeted Amphiphile-Immunotherapy Enhanced Anti-Tumor Function and Eradicated Solid Tumors

Elicio Therapeutics Announces Publication of Preclinical Data Demonstrating TCR-T Cell Therapy in Combination with Lymph Node-Targeted Amphiphile-Immunotherapy Enhanced Anti-Tumor Function and Eradicated Solid Tumors

Published data shows lymph node-targeted Amphiphile (“AMP”)-peptide and CpG combination with TCR-T cell therapy led to complete eradication and durable...